Locations:
Search IconSearch
May 23, 2017/Neurosciences

Treatment of Sleep-Disordered Breathing in Patients with Neuromuscular Disease

A review of our approach

Twitter-170116-16-NEU-1945-Walia-650×450-478297788

By Loutfi S. Aboussouan, MD, FCCP, and Eduardo Mireles-Cabodevila, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

More than 40 percent of patients with neuromuscular disease suffer from sleep-disordered breathing events. The more advanced the disorder, the higher the prevalence of sleep-related breathing issues from common neuromuscular disease features like anatomic or neurologic propensity to obstructive sleep apnea, potential cardiomyopathy and diaphragmatic weakness.

In a recent review in CHEST, we discuss common pathophysiology we see in our neuromuscular diseases clinic, which incorporates expert physicians from Cleveland Clinic’s Sleep Disorders Center, Respiratory Institute and Neurological Institute as well as experienced respiratory and physical therapists.

Sleep and neuromuscular disease

Patients with neuromuscular disease often exhibit varying degrees of restrictive physiology on pulmonary function testing. Lung restriction typically begins early in the disease course with a decrease in vital and inspiratory capacities. Further reduction of the vital capacity in the supine position and a decrease in chest wall compliance contribute to this restrictive physiology.

Respiration is particularly vulnerable during sleep when lung volumes are further reduced due to the combined effects of the neuromuscular disease, the supine position and the physiologic processes of sleep itself. Patients with neuromuscular disease are more vulnerable to the normal loss of inspiratory intercostal muscle tone during rapid eye movement (REM) sleep. Reduced chemosensitivity and reduced activity of pharyngeal dilators during sleep also compromise respiration during REM sleep.

A variety of sleep-disordered conditions are associated with the various neuromuscular diseases. These are highlighted in the table below, along with the mechanisms responsible for the development of these complications. The table is intended to be representative rather than exhaustive.

Advertisement

Types of sleep-disordered breathing in representative neuromuscular conditions categorized by site of disease.

Treating sleep-disordered breathing

We use a specific protocol to analyze patients with neuromuscular disease who undergo a sleep study. Our hypoventilation protocol includes transcutaneous monitoring of carbon dioxide levels and is specifically designed to address both obstructive events and hypoventilation.

We also work to reduce treatment burden on our patients. Many of our patients, especially those with amyotrophic lateral sclerosis (ALS), face multiple therapies and appointments. Accordingly, our neuromuscular clinic coordinates with the multidisciplinary ALS/motor neuron disease clinic of the Neuromuscular Center so that visits with physiatrists, social workers, therapists, neuromuscular and pulmonary physicians and pulmonary function testing are accomplished in a single day.

Our clinic specializes in providing all modalities of invasive and noninvasive ventilation. We use noninvasive mechanical ventilation and tailor the therapy to the patient’s needs. Our aim is to maintain patient autonomy and allow mobility, travel and speech. We also use diverse interfaces (oral, nasal, full face masks) and modes (volume- or pressure-controlled modes, including some automatic algorithms like Average Volume Assured Pressure Support [AVAPS]). We evaluate adherence and adjust the settings based on clinical signs, measurement of end tidal CO2 and nocturnal pulse oximetry. We use polysomnography to adjust settings in patients with complex issues. We monitor our patients carefully in the context of bulbar and cardiac dysfunction.

Attention to other pulmonary issues

In addition to sleep-related respiratory issues, our clinic focuses on secretion management and airway clearance. Much of the morbidity of neuromuscular diseases is related to the buildup of secretions and difficulties in their management. Options include control of secretions at their source (such as nasal spray), use of mucolytic agents that may reduce their viscosity (including nebulized treatments) and mechanical options that may facilitate their clearance (such as oscillatory valves or vest and cough-assist devices).

For a more in-depth discussion of sleep disorders associated with neuromuscular disease, their polysomnographic features, and treatment, read our full review in CHEST.

Dr. Aboussouan is staff in the Respiratory and Neurological Institutes and the Sleep Disorders Center. Dr. Mireles-Cabodevila is staff in the Respiratory Institute.

Advertisement

Related Articles

woman preparing for sleep study with healthcare provider
Study Illuminates Challenges of Multiple Sleep Latency Testing in Patients on REM-Suppressing Antidepressants

Nearly 80% of patients didn’t follow washout protocol, raising risk of misdiagnosis

brain vessels in primary angiitis of the CNS
Differentiating Primary CNS Angiitis From Atherosclerosis as a Cause of Stroke

Combining quantitative vessel wall MRI metrics, CSF abnormalities and neurologic symptoms can be highly predictive

older man being pushed in wheelchair
Study Documents Racial and Ethnic Gaps in Post-Acute Care for Stroke

Uninsured Hispanics least likely to be discharged to facility-based rehab or home healthcare

Dr. Amy Kunchok against decorative background
July 16, 2024/Neurosciences/Podcast
What to Know About Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) (Podcast)

It’s time to get familiar with this emerging demyelinating disorder

older man taking cognitive test on computer tablet
Self-Administered Screening Tool for Cognitive Dysfunction Rolled Out in Primary Care Clinics

Cleveland Clinic Cognitive Battery identifies at-risk patients during Medicare annual visits

receptor activity for myasthenia gravis medications
July 3, 2024/Neurosciences/Podcast
Myasthenia Gravis: Unmet Needs and Efforts to Address Them (Podcast)

An overview of associated antibodies, therapies for antibody-positive disease and the outlook for atypical forms of MG

woman on stationary exercise cycle
July 1, 2024/Neurosciences/PM&R
New Trial to Assess Forced Exercise for Subacute Stroke Recovery

Research to test clinical efficacy and cost-effectiveness versus standard-of-care rehab

vertebral hemangioma on MRI
Spine Stereotactic Radiosurgery for Symptomatic Vertebral Hemangiomas With Epidural Extension

Safety and efficacy demonstrated in largest case series reported to date

Ad